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the tubercle bacillus
Vijayashankar Nataraj, Cristian Varela, Asma Javid,
Albel Singh, Gurdyal S. Besra and Apoorva Bhatt*
School of Biosciences and Institute of Microbiology and
Infection, University of Birmingham, Edgbaston,
Birmingham B15 2TT, UK.
Summary
Mycolic acids are unique long chain fatty acids found
in the lipid-rich cell walls of mycobacteria including
the tubercle bacillus Mycobacterium tuberculosis.
Essential for viability and virulence, enzymes
involved in the biosynthesis of mycolic acids repre-
sent novel targets for drug development. This is par-
ticularly relevant to the impact on global health given
the rise of multidrug resistant and extensively drug
resistant strains of M. tuberculosis. In this review, we
discuss recent advances in our understanding of how
mycolic acid are synthesised, especially the potential
role of specialised fatty acid synthase complexes.
Also, we examine the role of a recently reported
mycolic acid transporter MmpL3 with reference to
several reports of the targeting of this transporter by
diverse compounds with anti-M. tuberculosis activity.
Additionally, we consider recent findings that place
mycolic acid biosynthesis in the context of the cell
biology of the bacterium, viz its localisation and
co-ordination with the bacterial cytoskeleton, and its
role beyond maintaining cell envelope integrity.
Introduction
The lipid-rich cell wall of Mycobacterium tuberculosis, the
bacterium that causes tuberculosis (TB), contains unique
fatty acids termed mycolic acids (Minnikin and Polgar,
1966; Barry et al., 1998; Daffe and Draper, 1998). These
long chain fatty acids, which have an alkyl side chain and a
hydroxyl group at the α and β positions respectively
(Fig. 1), are mainly found attached covalently to the dis-
tinctive peptidoglycan–arabinogalactan complex of the
mycobacterial cell wall. Additionally, mycolic acids are
constituents of outer cell envelope lipids including treha-
lose monomycolate (TMM), trehalose dimycolate (TDM)
and glucose monomycolate, and they can also be found as
free mycolic acids. Mycolic acids are derived from ‘house-
keeping’ fatty acids, i.e. those important for fundamental
cellular functions including cell membrane biosynthesis,
which are synthesised by a ‘eukaryotic-like’ modular type-I
fatty acid synthase termed FAS-I (Bloch, 1977). Mycobac-
terial FAS-I is bimodal and in addition to generating C18
fatty acids, M. tuberculosis FAS-I also synthesises C24–26
fatty acids (Bloch, 1977). The former can also be fed into a
second fatty acid synthase, the multienzyme, ‘prokaryotic-
like’ type-II fatty acid synthase, FAS-II, which eventually
generates a long chain fatty acid termed the merochain.
Malonyl-CoA is the building block used by both FASs and
its production requires acetyl-CoA and an acetyl-CoA car-
boxylase, AccD6 (Daniel et al., 2007). The malonate
moiety from malonyl-CoA is first transferred to an acyl
carrier protein (ACP) by the enzyme FabD prior to entering
the FAS-II pathway for merochain biosynthesis (Kremer
et al., 2001) via the proposed linking activity (so far only
demonstrated in vitro) of the ketoacyl synthase FabH (Choi
et al., 2000). FAS-II consists of ‘core’ reductive cycle
enzymes: a β-ketoacyl-ACP synthase, a β-ketoacyl-ACP-
reductase, a β-hydroxyacyl-ACP-dehydratase and an
enoyl-ACP-reductase that catalyse a reductive cycle using
malonyl-ACP as substrate to extend a growing acyl-ACP
chain by two carbons after each cycle, eventually yielding
a merochain of chain length up to C60. Finally, the mero-
chain is condensed with the FAS-I derived C24–26 fatty acid
by a polyketide synthase Pks13 (Gande et al., 2004;
Portevin et al., 2004), to yield an oxo-mycolic acid interme-
diate which is subsequently reduced by a mycolyl reduc-
tase to form a mature mycolic acid (Lea-Smith et al., 2007;
Bhatt et al., 2008). At some stage of this process, and it is
not currently known when, unknown desaturase(s) intro-
duce double bonds in the merochain, and subsequently
modifying enzymes that include methyl transferases and
cyclopropane synthases introduce modifications to the
merochain resulting in the formation of different mycolic
acid subclasses; M. tuberculosis produces three mycolic
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acid subclasses termed α, methoxy and keto mycolic acids
(Fig. 1). The monomycolylated glycolipid TMM serves as
both the carrier for mycolate transport (Grzegorzewicz
et al., 2012; Varela et al., 2012), as well as the substrate for
extracellular mycolyl transferases termed the Ag85
complex (Belisle et al., 1997; Puech et al., 2002).
Enzymes of the Ag85 complex are responsible for the
mycolylation of the arabinogalactan in the cell wall, as well
as formation of TDM. While early research on mycolic acids
was focussed on biochemical characterisation, the post
genome sequencing era and the development of genetic
tools for mycobacteria has resulted in a focus on identifying
genes involved in the biosynthesis of these unique fatty
acids. A vast majority of genes involved in mycolic acid
biosynthesis are essential and thus cannot be studied via
the generation of knockout strains. Though mycolic acids
are unique, they are not exclusive to mycobacteria, but are
also found in other related genera such as Nocardia,
Rhodococcus and Corynebacterium. Three microbial
species have particularly aided research into the genetic
determinants of mycolic acid metabolism (Marrakchi et al.,
2014). First, Corynebacterium glutamicum, by virtue of its
ability to survive in the absence of mycolic acid production,
has provided the opportunity to study viable mutants that
lacked mycolic acids (Gande et al., 2004). Second, the fast
growing saprophyte, Mycobacterium smegmatis has
proven useful in the establishment of tools for generating
conditional mutants, thus allowing us to study the loss of
function of essential genes (Bhatt et al., 2005). M. smeg-
matis is also far more tolerant to mutations altering cell wall
composition, which has been a particular advantage. And
finally, the leprosy bacillus Mycobacterium leprae, which
contains a ‘decayed’ genome, but produces mycolic acids,
has aided the ‘bioinformatic filtering’ of candidate genes
(Monot et al., 2005). However, some genes involved in
mycolic acid biosynthesis are non-essential in laboratory
growth conditions and these are predominantly involved in
merochain modification. M. tuberculosis mutants lacking
these modifying enzymes have proved useful in outlining
the importance of mycolic acids in immunomodulation,
virulence and influencing host pathology (Dubnau et al.,
2000; Glickman et al., 2000; Rao et al., 2005; 2006). Addi-
tionally, M. tuberculosis has two genes that each encode a
β-ketoacyl-ACP synthase, a core FAS-II enzyme. While
one of these genes, kasA, is essential (Bhatt et al., 2005),
the other, kasB, is not (Bhatt et al., 2007a). Interestingly,
the M. tuberculosis kasB null mutant produces shorter
mycolic acids, and while the mutant was severely attenu-
ated, it was able to persist in mice without displaying any of
the tissue pathology associated with infection (Bhatt et al.,
2007a).
The essentiality of mycolic acids for viability and for
virulence highlights the potential of components of the
mycolic acid biosynthesis machinery as attractive drug
Fig. 1. A. Fundamental structure of a mycolic acid shown using M. tuberculosis α-mycolic acid as an example.
B. Structures of other mycolic acid subclasses from M. tuberculosis.
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targets. While isoniazid, the hallmark anti-TB drug that
targets the FAS-II enoyl-ACP-reductase InhA has been in
use for many years, mycolic acid biosynthesis pathways
remain largely untapped as drug targets. This is especially
timely and relevant given the rise of multidrug resistant
and extensively drug resistant strains of M. tuberculosis
(MDR-TB and XDR-TB), and more worryingly the relatively
recent reports of ‘untreatable’ TB (Udwadia et al., 2012).
While there have been numerous reviews on the cell wall of
mycobacteria, very few have focussed exclusively on
mycolic acids. Takayama and colleagues wrote the first
comprehensive post-genome sequence review that not
only collated existing knowledge about mycobacterial
mycolic acid biosynthesis but also formulated hypothesis
about yet unidentified processes using bioinformatic
searches (Takayama et al., 2005). The field has advanced
rapidly since that review in 2005, and more recently
Marrakchi et al. (2014) have offered a comprehensive
review of these advances. The aim of this microreview is
not to replicate the information contained in these earlier
reviews. Instead we wish to reflect on advances made in
the field since the latter half of 2013. We also consider the
broader implications of these findings in terms of how they
advance our understanding of mycolic acid biosynthesis in
context of the biology of the bacterium, including higher
order structures and integration with the cell biology of the
bacterium.
Fatty acids and hotdogs: ﬁnding the elusive dehydratase
Core components of a FAS-II complex typically contain
four enzymes constituting a reductive cycle that catalyzes
the extension of an acyl-ACP chain by two carbons. While
three of the four components (KasA/KasB, MabAand InhA)
for the merochain producing mycobacterial FAS-II had
been identified by the late 1990s, until late the dehydratase
catalysing conversion of β-hydroxyacyl-ACP to enoyl-ACP
remained unidentified. The two operons harbouring the
genes encoding the other three core FAS-II components
(InhA and MabA, and KasA/KasB) do not include genes
with homology to FabZ or FabA, the classic dehydratase or
dehydratase–isomerase enzymes found in FAS-II com-
plexes from other bacteria (Rock and Cronan, 1996). Fur-
thermore, no fabZ or fabA homologues were found in the
genome of M. tuberculosis H37Rv, suggesting that the
dehydratase activity of FAS-II in M. tuberculosis and other
mycobacteria may be resulting from a dehydratase
with a different or alternative enzymatic motif. A break-
through came from a bioinformatic study that queried the
role of 11 genes encoding putative R-specific hydratase/
dehydratase family, in the biosynthesis of mycolic acids
(Castell et al., 2005). All contained a ‘hot dog’ fold that
resembled the structure of FabA/Z, but contained a distinct
catalytic site. Of these, only one gene, Rv0636 was present
in other mycolic acid producing genera and was demon-
strated by Sacco et al. (2007) to be an essential gene and
a dehydratase involved in mycolic acid biosynthesis. In a
parallel study, Brown et al. (2007a and 2007b) used a
drugs-to-target approach to demonstrate the role of
Rv0636 by showing that mycobacterial strains overex-
pressing Rv0636 showed resistance to flavonoids known
to target β-hydroxyacyl-ACP dehydratases in Escherichia
coli and Plasmodium. Furthermore, the functional dehy-
dratase component was shown to compose of a heterodi-
mer of Rv0636 (HadB) with either Rv0635 (HadA) or
Rv0637 (HadC). Both HadA and HadC also contain a
hotdog fold and functional heterodimers thus have a
‘double hotdog’ fold. These asymmetric double hotdog
folds are thought to play a dual role, with one (HadB)
required for catalysis, and the other (from HadA or HadC)
functioning as a stabiliser of long chain acyl groups that are
typical of mycolic acids. This model has been lent further
credence following the recently solved 3D structure of the
HadA–HadB complex (Biswas et al., 2015). Furthermore,
analogous to KasA and KasB (Kremer et al., 2002; Bhatt
et al., 2007b), the two heterodimeric complexes HadA–
HadB and HadB–HadC would be expected to differ in their
specificities for different fatty acyl chain lengths, with the
latter functioning to extend longer growing chains.
Recently, Carrère-Kremer et al (2015) demonstrated the
presence of a second dehydratase, not found in M. tuber-
culosis, but present in non-tuberculous mycobacteria
(NTMs) including M. smegmatis (MSMEG_6754). The role
of this non-essential dehydratase, which is a ‘fused’ HadA–
HadB-like peptide, remains unclear but it was able to
compensate for the loss of hadB in M. smegmatis. The
authors were able to generate a mutant of hadB in
M. smegmatis only when a chromosomally integrated, and
constitutively expressed second copy of MSMEG_6754
was present in the strain, indicating a functional redun-
dancy with hadB. Interestingly, the recombinant strain did
display an accumulation of shorter mycolic acid precur-
sors, in addition to mycolic acid subspecies usually found
in this fast growing species. However, the inability of this
second dehydratase to rescue viability during attempts to
generate a hadB knockout suggested a low level of func-
tional protein encoded by MSMEG_6754 was present in
wild-type M. smegmatis cells growing in laboratory condi-
tions, and implied a regulatory mechanism controlling its
expression. Indeed, MSMEG_6754 was essential for sur-
vival in amoebae suggesting a specialised environmental
role for this dehydratase in NTMs (Carrère-Kremer et al.,
2015).
There are many FAS-IIs
Takayama et al. (2005) first suggested the presence of
three FAS-II ‘modules’ including a core elongation FAS-II
Mycolic acids and the tubercle bacillus 3
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consisting of FabD, a β-ketoacyl-ACP synthase (KasA/
KasB), MabA, InhA and, at the time unidentified, dehy-
dratase component. Additionally, specialised FAS-IIA and
FAS-IIB modules capable of elongation were hypoth-
esised to be involved in the addition of cis unsaturations
at distal and proximal position on the meromycolate
chain respectively. The authors suggested that mycolic
acid biosynthesis proceeds along linear ‘assembly line’
arrays similar to type-II polyketide synthases, and that
there are five such linear arrays, each terminating with a
final condensation reaction catalysed Pks13. Each of
these arrays, containing differing combinations of FAS-II,
FAS-IIA, FAS-IIB and modifying enzymes, was dedicated
for the biosynthesis of one subclass of M. tuberculosis
mycolic acids. The five arrays were thus involved in the
biosynthesis of α mycolic acids, cis-methoxy mycolic
acids, trans-methoxy mycolic acids, cis-keto mycolic
acids and trans-keto mycolic acids. Experimental proof
indicating the presence of such complexes came from
protein–protein interaction studies conducted using
the yeast two-hybrid and three-hybrid systems, and in
vitro co-immunoprecipitation studies using individual
FAS-II components (Veyron-Churlet et al., 2004; 2005;
Cantaloube et al., 2011). Cantaloube et al. (2011)
extended earlier studies to define a ‘mycolic acid biosyn-
thesis interactome’ consisting of different specialised
FAS-II elongation complexes, all of which contained a
‘core’ consisting of MabA, InhA and FabD (Fig. 2). An
initiation FAS-II (I-FAS-II) contains, in addition to the
core, FabH and links FAS-I to FAS-II (Fig. 2). Two elon-
gation complexes contain the core and either KasA and
HadA–HadB (E1-FAS-II), or KasB and HadB–HadC (E2-
FAS-II). E1-FAS-II is proposed to carry out the initial
elongation cycles, with E2-FAS-II acting as unit for
further elongation of meroacyl chains produced by
E1-FAS-II (Fig. 2). Finally, a ‘termination’ FAS-II complex
involves Pks13 (Fig. 2), resulting in the Claisen conden-
sation of a meromycolate chain with a FAS-I derived C26
fatty acid to yield an oxo-mycolic acid which is subse-
quently reduced by the mycolyl reductase encoded by
Rv2509, to yield a mature mycolic acid moiety (Fig. 2).
Furthermore, these studies have also shown that
enzymes introducing modifications, such as methyltrans-
ferases, isomerases and cyclopropane synthases also
interact with the elongation complex, suggesting that
merochain modification occurs during elongation. Addi-
tionally, these modification enzymes show a preference
for a particular type of Had heterodimer and conse-
quently the type of elongation FAS-II complex. CmaA2
and PcaA that introduce modifications to the proximal
position of the merochain interact preferentially with
HadBC, whereas MmaA3, the enzyme involved in the
introduction of a methoxy group at the distal position,
interacts preferentially with the HadA–HadB heterodimer.
Mycolic acid transporters
While there has been considerable progress in the past two
decades towards identifying genes involved in the biosyn-
thesis of mycolic acids, mechanisms for their transport to
the outside of the mycobacterial cell remained unknown.
Takayama et al. (2005) had hypothesised that mycolic
acids were likely transported in the form of TMM. The
M. tuberculosis H37Rv genome encodes a class of mem-
brane proteins termed mycobacterial membrane proteins
large (MmpL), which are part of the resistance-nodulation-
division (RND) family of efflux pumps (Cole et al., 1998;
Domenech et al., 2005). Many of the 14 mmpL genes of
M. tuberculosis are located adjacent to biosynthesis clus-
ters for cell wall-associated glycolipids, and have been
shown to be transporters for the cognate lipids (Cox et al.,
1999; Converse et al., 2003; Domenech et al., 2004;
Belardinelli et al., 2014). We reckoned that TMM, also a
glycolipid, was likely transported by a MmpL, and given the
essentiality of mycolic acids for viability, the gene encoding
this MmpL would be essential. Previous, unsuccessful
attempts to generate a mutant of the gene mmpL3
(Rv0205c) (Domenech et al., 2005), and its presence in
the decayed M. leprae genome suggested that if an MmpL
was involved in TMM transport, MmpL3 was the likely
candidate for this function. Indeed we were able to dem-
onstrate that mmpL3 is essential in mycobacteria, and that
conditional depletion of MmpL3 in M. smegmatis led to the
intracellular accumulation of TMM (Varela et al., 2012). In
parallel to our studies, Grzegorzewicz et al (2012) and
Tahlan et al. (2012) identified MmpL3 as a target for novel
anti-TB drug candidates and subsequently demonstrated
its role in as a translocator of TMM across the mycobacte-
rial membrane. Whether MmpL3 is sufficient for the trans-
port of TMM remains to be determined. However, recent
findings from C. glutamicum indicate that transport of
mycolates may be a complex process. Yamaryo-Botte
et al. (2015) showed that transient acetylation of the
mycolyl moiety of trehalose monocorynomycolate (TMCM)
was necessary for its subsequent transport across the
corynebacterial membrane. Homologues of the TMCM
acetyltransferase are present in mycobacteria, suggesting
a similar process may occur in mycobacterial TMM
transport.
Located in the same cluster as mmpL3 is another
mmpL gene, mmpL11, which was shown to be non-
essential (Domenech et al., 2005; Owens et al., 2013).
However, a mutant of mmpL11 in M. smegmatis was defi-
cient in the transport of the less abundant monomeromy-
colyl diacylglycerol and a mycolate containing wax ester,
and showed accumulation of MycPL (a proposed intrac-
ellular carrier of mycolic acids), indicating a role for
MmpL11 in transport processes related to mycolic acid
containing lipids (Pacheco et al., 2013). Interestingly both
4 V. Nataraj et al. ■
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MmpL3 and MmpL11 have also been shown to play a role
in heme transport, suggesting that they may have multiple
roles in M. tuberculosis (Owens et al., 2013).
Co-ordination with polar growth
Mycobacteria, unlike other rod shaped bacteria such as
Bacillus, exhibit polar growth where nascent peptidoglycan
is synthesised and deposited at the poles during cell
elongation (Kang et al., 2008). The tropomyosin-like
protein Wag31 (orthologue of Bacillus DivIVA) plays an
important role in co-ordinating polar growth; the protein
localises to the tip of growing poles of mycobacterial cells
and interacts with enzymes involved in cell wall biosynthe-
sis (Kang et al., 2008; Jani et al., 2010). Two key papers
have now shown that this interaction also involves compo-
nents of the mycolate synthesising machinery. Carel et al.
(2014) used GFP-fusions of the FAS-II components MabA,
InhAand KasA to show that enzymes of the reductive cycle
co-localise with Wag31 at the ‘old’ growing poles. The
authors also showed a fivefold enrichment of the mycolate
transporter MmpL3 at the polar membranes. Meniche et al.
(2014) took a different approach to identify additional com-
ponents of the mycolic acid biosynthesis machinery that
localise at the growing tips. Co-purification experiments
with endogenously tagged Wag31 and Pks13 in M. smeg-
matis revealed a polar complex consisting of AccA3,
AccD4 and AccD5, members of an acyl-CoA carboxylase
(ACC) complex, Pks13 and FadD32, all enzymes required
for the final stages of production of a nascent mycolic acid.
The positions of the ACC components coincided with
Wag31. However, Pks13 and FadD32 were found in a
‘subpolar’ location, suggesting that the Wag31-associated
complex and the terminal mycolate biosynthesis enzymes
occupied exclusive regions of the polar tip, with new
mycolic acids being deposited at a subpolar location in a
growing tip.
Beyond the wall
Given the abundance of mycolic acids in the lipid-rich
mycobacterial cell wall, it is tempting to assume that their
role is limited to the structural integrity of the cell envelope.
However, we now have a better understanding of the
extended role played by mycolic acids, particularly TDM, in
manipulating the host immune system and driving pathol-
ogy during infection (reviewed extensively by Marrakchi
et al., 2014). Mycolic acids have also been shown to play a
role in the formation of biofilms often referred to as pellicu-
lar growth. The first link between pellicle formation and
mycolic acids came from studies on a mutant strain of
M. smegmatis that was deficient in the production of a
GroEL1, a non-essential chaperone in mycobacteria. The
GroEL1 mutant was unable to form a pellicle on a liquid–air
interface in a laboratory broth medium and displayed an
altered mycolic acid profile (Ojha et al., 2005). Further-
more, GroEL1 was shown to directly interact with the
FAS-II enzyme, KasA. Mycolic acid composition also
affects pellicle formation; a strain deficient in keto-mycolic
acid formation was unable to form pellicles (Sambandan
et al., 2013). Furthermore, the mmpL11 mutant of
M. smegmatis that failed to transport monomeromycolyl
diacylglycerol and a mycolate containing wax ester was
defective in biofilm formation (Pacheco et al., 2013). Myco-
lates are not the only lipids to influence pellicle/biofilm
formation; however, the enrichment of free mycolic acids in
pellicles of mycobacteria showed that they play a signifi-
cant role in the formation of this structure (Ojha et al.,
2008).
Targeting the Achilles’ heel: developing drugs that inhibit
mycolate metabolism
Unique components of bacteria that are also essential
represent ideal drug targets as they allow development of
drugs that specifically inhibit the aetiological agent of
disease, while leaving the normal flora intact. In this regard,
M. tuberculosis mycolic acids fulfil both these criteria.
Indeed, the hallmark anti-TB drug targets InhA, the core
FAS-II component (Banerjee et al., 1994). However, in the
past 15 years a number of other inhibitors targeting other
mycolate biosynthesis components have been described
(reviewed by Marrakchi et al., 2014). These include com-
pounds that target enzymes involved in mycolic acid con-
densation (Pks13, FadD32), and those involved in the
biosynthesis/elongation of the fatty acyl chain (AccD5,
AccD6, KasA/KasB, InhA, HadA, HadB, HadC, Ag85).
Surprisingly, some targets have also included ‘non-
essential’ components; the compound dioctylamine inhib-
ited multiple methyltransferases involved in mycolic acid
modification, resulting in a loss of all mycolic acid cyclo-
propanation and cell death (Barkan et al., 2009). This was
surprising as individual genes involved in mycolic acid
cyclopropanation were not essential for growth, leading to
the authors to suggest that loss of viability was likely due to
the deleterious effect of loss of cyclopropanation on mem-
brane fluidity. Similarly, thiacetazone was also shown to
inhibit cyclopropanation of mycolic acids (Alahari et al.,
2009). However, more recently, the focus of anti-TB drug
discovery has been on the TMM transporter, MmpL3. This
is because spontaneous mutants resistant to a diverse
group of compounds with anti-M. tuberculosis activity were
found to contain mutations in the mmpL3 gene (Li et al.,
2014). The first report was that of SQ109, a diamine,
developed from the combinatorial library of ethambutol,
which showed potent activity against drug-sensitive and
drug-resistant mycobacteria (Protopopova et al., 2005).
Subsequently, Tahlan et al. (2012) showed that SQ109
treatment led to TMM accumulation in M. tuberculosis and
6 V. Nataraj et al. ■
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spontaneous SQ109-resistant mutants contained single
nucleotide polymorphisms (SNPs) in the mmpL3 gene.
Shortly thereafter, there were two reports of drugs targeting
M. tuberculosis, the pyrrole derivative BM212 and the
adamantly urea compound AU1235 (Grzegorzewicz et al.,
2012; La Rosa et al., 2012). Mutants resistant to either
compound were shown to harbour a mutated mmpL3
allele. However, the divergent scaffolds from which the
different inhibitors were derived, and their broad-spectrum
activity against non-mycolate producing bacteria and
fungal species, suggested that MmpL3 was probably not
the direct target of these inhibitors. As mentioned earlier,
MmpL3 and other mycobacterial MmpLs are members of
the RND superfamily of proteins that require a proton
motive force (PMF) for function. Li et al. (2014) have shown
that SQ109 causes a dissipation of PMF in M. tuberculosis,
thus disrupting MmpL3 function. Furthermore, exposure to
SQ109 also led to reduction in lipid export by MmpL8 and
MmpL10, indicating that effects of SQ109 were not
MmpL3-specific. This finding of a broader effect of SQ109
on multiple targets was at odds with the consistent isolation
of resistant mutants with SNPs in mmpL3. The authors
suggested that spontaneous mutants that are resistant to
SQ109 (and other compounds) result from mutations in
mmpL3 as an early response to counteract toxic effects of
these compounds (Li et al., 2014). Indeed these mutations
mapped close to those predicted to participate in the proton
gradient required for translocation of substrate. In light of
several other reports of SNPs in mmpL3 leading to resist-
ance to diverse compounds, the idea that these are exclu-
sively MmpL3 (and thus mycolic acid transport) targeting
compounds needs to be revisited. The mycolic acid bio-
synthesis complex represents a unique target, one that is
currently rendered unexploited in MDR-TB and XDR-TB
strains (due to resistance to isoniazid). Further work on
current known inhibitors of the enzymes mentioned earlier
in this section will pave the way towards new inhibitors of
mycolic acid biosynthesis.
Future perspectives
A majority of the enzymatic components required for
mycolic acid biosynthesis have now been identified;
however, there are still some stages in mycolate metabo-
lism that remain poorly understood. These include the
process of introducing double bonds in merochains, and
the enzymes involved in post-Pks13 processing of mycolic
acids that ultimately leads to the formation of TMM.
However, in parallel, our understanding of mycolic acid
biosynthesis and transport in context of a higher order of
structures has been initiated by in vitro studies to detect
interactions between FAS-II components and other
enzymes involved in the biosynthesis process. With the
advance of microscopy techniques that enable visualisa-
tion of complexes in single bacterial cells, it is likely that
such complexes may one day be demonstrated in vivo.
Such studies could also indicate whether biosynthesis
occurs at localised complexes that also integrate transport.
A better understanding is also required of the co-ordination
of this process with polar growth, and with peptidoglycan
and arabinogalactan deposition in the cell wall during cell
division. These studies could potentially also open alterna-
tive avenues for targeting mycolic acid assembly via the
design of complex-disrupting inhibitors. Furthermore, the
regulation of mycolic acid biosynthesis has only just begun
to be unravelled. Regulation of activities of FAS-II enzymes
following post translation modification by Ser/Thr protein
kinase-mediated phosphorylation has been studied exten-
sively in vitro (Veyron-Churlet et al., 2009; Khan et al.,
2010; Molle and Kremer, 2010; Molle et al., 2010; Slama
et al., 2011; Corrales et al., 2012), and advances in ‘knock
in’ methodologies have initiated studies to conduct the
same in vivo (Vilcheze et al., 2014). While the transcrip-
tional regulator MabR is known to regulate mycolic acid
biosynthesis in vitro (Salzman et al., 2010), it is not known
if transcription of merochain modification enzymes is regu-
lated in vivo, resulting in changes to ratios of mycolic acid
subclasses. In summary, this waxy ‘brick’ in the mycobac-
terial cell wall continues to be a focus of research on the
tubercle bacillus, as we attempt to develop new and better
therapies for this ancient disease.
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